Effects of captopril, spironolactone, and simvastatin on the cardiovascular system of non-diseased Wistar rats

International Journal of Cardiology

Volumn 190, Issue 1, 2015, Pages 128-130

  Simko, Fedor ^a,b,c   Pechanova, Olga ^c,d   Krajcirovicova, Kristina ^a   Matuskova, Jana ^a   Pelouch, Vaclav ^e   Adamcova, Michaela ^e   Paulis, Ludovit ^a,c  

^a Faculty of Natural Sciences   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^c Center of Excellence NOREG   (Slovakia)

^d INSTITUTE OF CHEMISTRY   (Slovakia)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Captopril; Endothelial function; Fibrosis; Non diseased heart; Protection; Protein remodeling; Simvastatin; Spironolactone

Indexed keywords

CAPTOPRIL; NITRIC OXIDE SYNTHASE; SIMVASTATIN; SPIRONOLACTONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINERALOCORTICOID ANTAGONIST;

ARTICLE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; DIAGNOSTIC ERROR; DRUG EFFECT; DRUG MISUSE; ENZYME ACTIVITY; GLOMERULUS; HEART LEFT VENTRICLE; HEART PROTECTION; HUMAN; LONG TERM CARE; NONHUMAN; POLYPHARMACY; PRIMARY PREVENTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WISTAR RAT; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; HEART VENTRICLE REMODELING; MALE; PHYSIOLOGY; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CAPTOPRIL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RATS; RATS, WISTAR; SIMVASTATIN; SPIRONOLACTONE; VENTRICULAR REMODELING;

EID: 84929466621     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.092     Document Type: Article

References (14)

1. M.R. Cowie, A.D. Struthers, D.A. Wood, A.J. Coats, S.G. Thompson, P.A. Poole-Wilson, et al., Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care, Lancet 350 (1997) 1349-1353.
2. J. Hodgkinson, J. Mant, U. Martin, B. Guo, F.D. Hobbs, J.J. Deeks, et al., Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review, BMJ 24 (2011) d3621.
3. B. Wiley, V. Fuster, The concept of the polypill in the prevention of cardiovascular disease, Ann. Glob. Health 80 (2014) 24-34.
4. T. Oliveras Vilà, M. Ferrer Massot, A. Curós Abadal, F. Rueda Sobella, J. Serra Flores, X. Carrillo Suárez, et al., Real-life use of the polypill components (ASA + ACEI + statins) after an acute coronary syndrome and long-term mortality, Int. J. Cardiol. 177 (2014) 209-210.
5. N.J. Wald, M.R. Law, A strategy to reduce cardiovascular disease by more than 80%, BMJ 326 (2003) 1419.
6. M. Lafeber, D.E. Grobbee, I.M. Schrover, S. Thom, R. Webster, A. Rodgers, et al., Int. J. Cardiol. 181 (2014) 193-199.
7. V. Pelouch, M. Milerova, B. Ostadal, B. Hucin, M. Samanek, Differences between atrial and ventricular protein profiling in children with congenital heart disease, Mol. Cell. Biochem. 147 (1995) 43-49.
8. G.K. Reddy, C.S. Enwemeka, A simplified method for the analysis of hydroxyproline in biological tissues, Clin. Biochem. 29 (1996) 225-229.
9. D.S. Bredt, S.H. Snyder, Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme, Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 682-685.
10. F. Simko, Statins - a perspective for left ventricular hypertrophy treatment, Eur. J. Clin. Investig. 37 (2007) 681-691.
11. F. Simko, O. Pechanova, V. Pelouch, K. Krajcirovicova, M. Mullerova, K. Bednarova, et al., Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats, J. Hypertens. 27 (2009) S5-S10.
12. K.T. Weber, Y. Sun, S.K. Bhattacharya, R.A. Ahokas, I.C. Gerling, Myofibroblast-mediated mechanisms of pathological remodelling of the heart, Nat. Rev. Cardiol. 10 (2013) 15-26.
13. F. Simko, L. Paulis, Hypertensive heart disease: bone marrow as a significant player in pathologic remodelling? J. Hypertens. 30 (2012) 1702-1705.
14. F. Simko, L. Paulis, Antifibrotic effect of melatonin-perspective protection in hypertensive heart disease, Int. J. Cardiol. 168 (2013) 2876-2877.